In Reply While commenting on our article published in JAMA Psychiatry,1 Glue et al raise the issue that “dietary benzoic acid intake may be a significant confounding variable that needs to be considered in interpreting the outcome of this study.” First, the double-blind placebo-controlled design confirmed that the add-on treatment of benzoate is much more efficacious than placebo in improving symptoms and cognition in schizophrenia. It is apparent that both groups had received benzoate from their daily intake of food and drink; however, the active treatment group received a 1000-mg sodium benzoate supplement a day, while the placebo group did not.
Tsai GE. Impact of Dietary Benzoic Acid on Treatment Response in Schizophrenia—Reply. JAMA Psychiatry. 2014;71(11):1299. doi:10.1001/jamapsychiatry.2014.709